Metastatic castration-resistant prostate is an advanced form of the cancer that’s incurable. Learn about treatment options ...

Experts developed consensus recommendations through the modified Delphi process for metastatic prostate cancer management ...

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

Full abstracts will be released by ASCO on Thursday, May 22, 2025, at 5:00 PM ET. Details from the presentations will be available following the event on the Candel website at Candel Media. * Dr.

The hope is the therapy can effectively target cancerous cells at relatively small doses while minimizing side effects.

Nearly all men with a polygenic risk score in the 90th percentile or above had a 10-year absolute risk for prostate cancer exceeding 3.8%. A polygenic risk score (PRS) identifies more patients with ...

Prostate cancer is a common type of cancer in males, but it is highly treatable in the early stages. It begins in the prostate gland, which sits between the penis and the bladder. Experts do not ...

Medically reviewed by Jamin Brahmbhatt, MD The treatment of metastatic castration-resistant prostate cancer (mCRPC) involves ...